Discovery Early Career Researcher Award - Grant ID: DE140101553
Funder
Australian Research Council
Funding Amount
$395,220.00
Summary
A flexible virus-like particle delivery platform for next-generation vaccines. Murine polyomavirus (MPyV) capsid proteins self-assemble into spherical protein shells approximately 45 nm in diameter. Such virus-like particles (VLPs) are of considerable interest as bionanotechnological tools. The unique flexibility provided by MPyV VLPs will be exploited by exploring the ability of the interior cavity to retain bioactive cargos while engineering novel functionality on the exterior surface by 'mix- ....A flexible virus-like particle delivery platform for next-generation vaccines. Murine polyomavirus (MPyV) capsid proteins self-assemble into spherical protein shells approximately 45 nm in diameter. Such virus-like particles (VLPs) are of considerable interest as bionanotechnological tools. The unique flexibility provided by MPyV VLPs will be exploited by exploring the ability of the interior cavity to retain bioactive cargos while engineering novel functionality on the exterior surface by 'mix-and-match' assembly of VLPs from modified components. As a proof of concept for next-generation vaccines that stimulate much needed, broadly protective responses against infectious diseases, model antigens will be delivered to specific immune cells using this nano-container.Read moreRead less
Improving immune response to vaccines by selective targeting of epithelial regions with the Nanopatch. Vaccination protects us from infections like measles and flu. In principle, it could protect us from all diseases, even from skin cancer and arthritis. In practice, however, vaccines to diseases like cancer have largely proved ineffective. One problem is that we don't really understand how the body's immune system responds to vaccination. Our aim, therefore, is to investigate changes in the imm ....Improving immune response to vaccines by selective targeting of epithelial regions with the Nanopatch. Vaccination protects us from infections like measles and flu. In principle, it could protect us from all diseases, even from skin cancer and arthritis. In practice, however, vaccines to diseases like cancer have largely proved ineffective. One problem is that we don't really understand how the body's immune system responds to vaccination. Our aim, therefore, is to investigate changes in the immune system when a vaccine enters the skin, as might happen by injection. Experimenting with laboratory mice and a special vaccine-injecting Nanopatch that is attached to each mouse's ear, we are starting to understand how a vaccine affects the immune cells in the skin. In the future we plan to apply this knowledge to improve vaccination in people.Read moreRead less
Optimising the body's immune response with a Nanopatch that delivers biomolecules to the skin. The team is developing a new improved way to vaccinate against deadly infectious diseases such as influenza and malaria. They believe their Nanopatch technology will boost the power of seasonal influenza vaccination and could even solve vaccine shortages in an influenza pandemic. This is because the Nanopatch needs much less vaccine per person than a conventional syringe. They also predict that vaccine ....Optimising the body's immune response with a Nanopatch that delivers biomolecules to the skin. The team is developing a new improved way to vaccinate against deadly infectious diseases such as influenza and malaria. They believe their Nanopatch technology will boost the power of seasonal influenza vaccination and could even solve vaccine shortages in an influenza pandemic. This is because the Nanopatch needs much less vaccine per person than a conventional syringe. They also predict that vaccines delivered with a Nanopatch will require less refrigeration than conventional vaccines and can be safely administered by individuals without medical training, making the benefits of vaccination accessible to more people more cheaply, even in remote areas.Read moreRead less
Micro-nanoprojection patches for minimally-invasive and targeted delivery of genes and drugs to skin cells: from concept to technology platform. This project will address key science questions on the recently patented micro-nanoprojections patch, establishing it in Australia as a world leading technology in the rapidly growing and important field of gene and drug delivery. Unique internationally-competitive science outcoumes and research training will be generated at the interfaces between bioen ....Micro-nanoprojection patches for minimally-invasive and targeted delivery of genes and drugs to skin cells: from concept to technology platform. This project will address key science questions on the recently patented micro-nanoprojections patch, establishing it in Australia as a world leading technology in the rapidly growing and important field of gene and drug delivery. Unique internationally-competitive science outcoumes and research training will be generated at the interfaces between bioengineering, nanotechnology, pharmaceutical science and immunology. Ultimately, the project will allow improved treatment of major diseases (e.g. vaccination and immunotherapy of asthma). Achieving these health benefits by commercial pathways is expected to benefit the Australian community and emerging Biotechnology industry-creating highly valued career opportunities for Australians.Read moreRead less